Approximately 1–2% of patients receiving checkpoint inhibitors develop new-onset autoimmune diabetes [86], characterised by rapid onset of hyperglycaemia, swift progression of endogenous insulin deficiency, and a high risk of DKA or severe hyperglycaemia if not detected and treated promptly with insulin therapy [87, 88]. This evidence concerns the gene INS and Hyperglycemia.